DexCom, Inc. (DXCM) Operating Cash Flow CAGR:N/A(TTM)
The operating cash flow cagr for DexCom, Inc. (DXCM) is N/A over the latest trailing 12-month period. Operating cash flow CAGR uses precomputed cash-flow statement history (cash from operations, before capital expenditures).
The operating cash flow CAGR for DexCom, Inc. (DXCM) stock is N/A over the past 12 months. The 3 year CAGR is 33.21% and the 5 year CAGR is 28.87%. Operating cash flow CAGR measures the compound annual growth rate of the cash DexCom, Inc. generates from its core business operations, before capital expenditures, computed from rolling-twelve-month cash-flow statement history. The 1-year (TTM) figure is omitted: a one-year rate off a single quarter's base is volatile; the multi-year figures are the reliable read.
DXCM Operating Cash Flow CAGR Chart
DexCom, Inc. (DXCM)
DXCM Operating Cash Flow CAGR History
| Year | Start OCF | End OCF | Change | % Change | CAGR |
|---|---|---|---|---|---|
| 2025 | $989.50M | $1.44B | +$451.20M | +45.60% | +45.60% |
| 2024 | $748.50M | $989.50M | +$241.00M | +32.20% | +32.20% |
| 2023 | $669.50M | $748.50M | +$79.00M | +11.80% | +11.80% |
| 2022 | $442.50M | $669.50M | +$227.00M | +51.30% | +51.30% |
| 2021 | $475.60M | $442.50M | $-33.10M | -6.96% | -6.96% |
| 2020 | $314.50M | $475.60M | +$161.10M | +51.22% | +51.22% |
| 2019 | $123.20M | $314.50M | +$191.30M | +155.28% | +155.28% |
| 2018 | $92.00M | $123.20M | +$31.20M | +33.91% | +33.91% |
| 2017 | $56.20M | $92.00M | +$35.80M | +63.70% | +63.70% |
| 2016 | $49.00M | $56.20M | +$7.20M | +14.69% | +14.69% |
| 2015 | $23.60M | $49.00M | +$25.40M | +107.63% | +107.63% |
| 2014 | $2.40M | $23.60M | +$21.20M | +883.33% | +883.33% |
| 2013 | $-33.10M | $2.40M | +$35.50M | +0.00% | N/A |
| 2012 | $-30.13M | $-33.10M | $-2.97M | +0.00% | N/A |
| 2011 | $-42.68M | $-30.13M | +$12.55M | +0.00% | N/A |
| 2010 | $-39.39M | $-42.68M | $-3.29M | +0.00% | N/A |
| 2009 | $-37.45M | $-39.39M | $-1.94M | +0.00% | N/A |
| 2008 | $-33.21M | $-37.45M | $-4.24M | +0.00% | N/A |
| 2007 | $-43.73M | $-33.21M | +$10.53M | +0.00% | N/A |
| 2006 | $-22.55M | $-43.73M | $-21.18M | +0.00% | N/A |
| 2005 | $-12.43M | $-22.55M | $-10.13M | +0.00% | N/A |
| 2004 | $-9.46M | $-12.43M | $-2.97M | +0.00% | N/A |
About DexCom, Inc.
DexCom, Inc. is a medical technology company primarily focused on innovating, developing, and marketing continuous glucose monitoring (CGM) systems. Operating across the United States and internationally, the firm provides its solutions for individuals managing diabetes as well as for healthcare practitioners. Its product portfolio features the DexCom G6, a comprehensive CGM system for diabetes management; the Dexcom Real-Time API, enabling authorized third-party developers to integrate live CGM data into their digital health applications; the Dexcom ONE, which aims to supersede traditional finger-prick blood glucose testing for treatment decisions; and Dexcom Share, a remote monitoring platform. The company is also developing the Dexcom G7, its next-generation CGM system. Furthermore, DexCom, Inc. has a licensing and collaboration agreement with Verily Life Sciences LLC and Verily Ireland Limited to advance blood-based or interstitial glucose monitoring products. The company directly sells its offerings to specialists such as endocrinologists, physicians, and diabetes educators. DexCom, Inc. was founded in 1999 and maintains its headquarters in San Diego, California.
- Sector
- Healthcare
- Industry
- Medical - Devices
- CEO
- Jacob Steven Leach